Boothbay Fund Management LLC Has $2.20 Million Stock Holdings in Encompass Health Co. (NYSE:EHC)

Boothbay Fund Management LLC trimmed its position in Encompass Health Co. (NYSE:EHC) by 67.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,869 shares of the company’s stock after selling 49,090 shares during the quarter. Boothbay Fund Management LLC’s holdings in Encompass Health were worth $2,204,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EHC. MassMutual Private Wealth & Trust FSB grew its holdings in Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after buying an additional 137 shares in the last quarter. Transce3nd LLC acquired a new position in Encompass Health in the 4th quarter valued at $40,000. CBIZ Investment Advisory Services LLC grew its holdings in shares of Encompass Health by 38.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock worth $42,000 after purchasing an additional 127 shares in the last quarter. Tompkins Financial Corp acquired a new stake in shares of Encompass Health during the 4th quarter worth $46,000. Finally, V Square Quantitative Management LLC grew its holdings in shares of Encompass Health by 43.8% during the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company’s stock worth $54,000 after purchasing an additional 177 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Price Performance

Encompass Health stock opened at $113.33 on Monday. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $11.41 billion, a PE ratio of 25.41, a P/E/G ratio of 2.31 and a beta of 0.87. Encompass Health Co. has a 12 month low of $82.38 and a 12 month high of $114.38. The stock has a 50-day moving average price of $100.08 and a two-hundred day moving average price of $98.57.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating the consensus estimate of $1.19 by $0.18. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. Analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Tuesday, April 1st were given a $0.17 dividend. The ex-dividend date was Tuesday, April 1st. This represents a $0.68 annualized dividend and a yield of 0.60%. Encompass Health’s dividend payout ratio is presently 15.25%.

Insider Buying and Selling at Encompass Health

In other news, CAO Andrew L. Price sold 5,042 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the transaction, the chief accounting officer now owns 69,164 shares in the company, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.10% of the company’s stock.

Analyst Ratings Changes

EHC has been the topic of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $110.00 target price on shares of Encompass Health in a report on Tuesday, February 11th. William Blair reissued an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. Barclays increased their target price on Encompass Health from $118.00 to $129.00 and gave the stock an “overweight” rating in a report on Friday. KeyCorp increased their target price on Encompass Health from $120.00 to $122.00 and gave the stock an “overweight” rating in a report on Friday. Finally, StockNews.com raised Encompass Health from a “hold” rating to a “buy” rating in a research note on Friday. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and an average target price of $113.14.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.